Virios Therapeutics Inc (VIRI)

[DavidLeeRoth]

Indeed😎

[valleybenedetto]

Ok. You can always get me on twitter

[Money-train]

Disclosure: I’m buying folks!

[DavidLeeRoth]

I don’t have PM anymore bud. I got it though👍

[valleybenedetto]

Sent you DM

[DavidLeeRoth]

Down 44% premarket🤮

[DavidLeeRoth]

Agreed. Maxim sucks ass! Not sure why they picked them for this offering😏

[valleybenedetto]

Maxim shorted this from .45 worst firm they could have gone with. I'm absolutely disgusted with Greg.

[DavidLeeRoth]

No, this is the offering they’re going with.

[zooey]

Is this in addition to the previous 2.1 million offering?

[DavidLeeRoth]

Disgusting to say the least

[DavidLeeRoth]

https://ir.virios.com/news/press-releases/detail/118/virios-therapeutics-announces-pricing-of-1-7-million

[DavidLeeRoth]

The long term possibilities are endless though, as they could bring in BILLIONS with these drugs.😎💰

[DavidLeeRoth]

I hear ya bud. He keeps dangling a partnership, but apparently it’s all just to get people to buy his stock.

[valleybenedetto]

As a mechanism to remove the CEO who has crushed market cap with his irresponsible funding attempts. If he raises this 2mil plus the 1.2m from the ATM he has raised 3.2 mil at the expense of 45 MIL IN MARKET CAP. Absolutely incompetent.

[DavidLeeRoth]

Please don’t take this the wrong way, but how do you sue a development-stage biotechnology company with no revenue?

[valleybenedetto]

Nothing like a good dose of incompetent management to fuck up a company. Lawsuits incoming.

[longrichard]

LOL

[zooey]

Agree, just hate how they say they have funding for the remainder of the year and then pull this..

[maq1214]

Tbf its a small offering shouldn’t be a problem if that expect positive Long Covid trials

[zooey]

Same shit they pulled after hours last time when we were at 2.40.. Like a pinky wrapped in a NASDAQ cloak..

[maq1214]

I gleaned that from CEO last call, my only concern is that put them at risk of an RS.

[DavidLeeRoth]

Sometimes you just have to show that you’re willing to do it all on your own.😎 VIRI LONG💰

[DavidLeeRoth]

We don’t know that for sure just yet.

[maq1214]

No partnership :(

[DavidLeeRoth]

Minuscule to say the least. VIRI is a LONG TERM STOCK.😎💰

[Money-train]

Virios Therapeutics Announces $2.1M Proposed Public Offering Of Common Stock

[DavidLeeRoth]

We have a pulse again! Let’s go TEAM VIRI😎💰

[maq1214]

are we expecting the results from the long covid trial this summer or late in the 2nd Half of 2024?

[DavidLeeRoth]

Good move on your part😎👍 We are way overdue for a blockbuster PR💰

[GREGG THE GREEK]

Been adding down at these levels too.


Was a fun trade before and I'm thinking we'll see another solid move at some point.
We shall see.


.35s

VIRI

[DavidLeeRoth]

Yeah! That one is pure insanity😳

[pinkslipjunkie]

Ok...time for this to pull a RNAZ for you all.

[DavidLeeRoth]

Well let’s hope you and your 🙀 don’t regret that decision. VIRI LONG💰

[limer814]

As my cat says .. meoowt

[DavidLeeRoth]

Keep selling!! I’m scooping up as much as I can.😎

[DavidLeeRoth]

You never know when that bombshell news could drop bud😎 Time will tell💰

[maq1214]

They appear to keep stretching out a partnership :(

[DavidLeeRoth]

Conference call starts in 10 minutes.

ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets. Management will also host a webcast and conference call on May 9, 2024 at 8:30 a.m. ET to discuss the results and provide a corporate update.
The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-506-0062 (domestic) or 973-528-0011 (international) and asking to be connected to the "Virios Therapeutics Conference Call" using the access code: 739495.

[limer814]

News out boys and girls

[Money-train]

As of March 31, 2024, Virios Therapeutics' cash totaled $2.4 million. The Company believes it will have sufficient resources to fund operations into the fourth quarter of 2024.

[Carjockey2]

Who wouldn't..

[Tiger Money]

I would love for another company to take my shares from me at a nice premium….

[DavidLeeRoth]

I’d shit my pants with that kind of excitement😎🤣

[maq1214]

Imagine we get a buyout or partnership this Thursday morning

[Tiger Money]

Odd

[limer814]

Yeah I bought half those shares but they didn't show up for an hour

[Tiger Money]

Yea I only see 4350 ish traded

[limer814]

Added a few thousand shares this am but it shows no volume..

[DavidLeeRoth]

Conference call May 9th Folks!!

ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets. Management will also host a webcast and conference call on May 9, 2024 at 8:30 a.m. ET to discuss the results and provide a corporate update.

The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-506-0062 (domestic) or 973-528-0011 (international) and asking to be connected to the "Virios Therapeutics Conference Call" using the access code: 739495.

About Virios Therapeutics

Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (“FM”) and Long-COVID (“LC”). Overactive immune response related to activation of tissue resident herpesvirus has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel syndrome, LC, chronic fatigue syndrome and functional somatic syndromes, all of which are characterized by a waxing and waning manifestation of disease, often triggered by events which compromise the immune system. The Company’s lead development candidates are novel, proprietary, fixed dose combinations of an antiviral compound and celecoxib designed to synergistically suppress herpesvirus replication, with the end goal of reducing virally promoted disease symptoms. IMC-1 (fixed dosage combination of famciclovir and celecoxib) has been granted fast track designation by the FDA.

For more information, please visit www.virios.com.